A novel mutation in the human aromatase gene: Insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment
Open accessAbstract
Objective Here we report on a new case of human aromatase deficiency in a man of 26 years of age and present the results of five year follow-up during trandermal estradiol (tE2) substitution, focusing on bone growth and mineralization. The lack of patient's compliance to tE2 treatment, resulting in low but detectable serum estradiol levels, provides helpful information about the physiological estradiol needed in serum to guarantee a complete bone maturation and mineralization. Design Clinical case report study. Methods Genetic, biochemical and hormonal evaluations and the study of bone health were performed before and during estrogen treatment. Results Eunuchoid body proportions, unfused epiphyses, tall stature, osteopenia, increase fasting insulin, mild astenozoospermia and a history of right cryptorchidism were present. Baseline serum FSH was slightly above the normal range and estradiol was undetectable. Genetic analysis revealed a pattern of compound heterozygosity due to 23 bp deletion in exon IV and a point mutation in the first nucleotide of intron IX of the CYP19A1 gene, respectively. The closure of epiphyseal cartilage, the normalization of bone BMD and bone turnover markers, and the improvement of insulin levels were reached during tE2 only when serum estradiol raised above 73 pmol/L. Sperm parameters and overweight did not improve with substitutive therapy. Conclusions This new case of aromatase deficiency underlines the role of estrogen on skeletal maturation, BMD, metabolic abnormalities and gonadal axis. It provides evidence on the need not only of a continuous estrogen replacement, but also of ensuring adequate estradiol levels in serum in order to ensure a complete bone maturation and mineralization and to prevent the worsening of body skeletal proportions. The comprehension of this physiological aspect has relevant clinical significance especially for the development of new therapeutic strategies useful to treat growth disorders by targeting serum estradiol in men.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
All adult aromatase-deficient men demonstrated a remarkably low bone mass.
“All adult aromatase-deficient men demonstrated a remarkably low bone mass and unfused epiphyses leading to linear growth into adulthood and above-average body length.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [18]
All adult aromatase-deficient men have unfused epiphyses leading to linear growth into adulthood and above-average body length.
“All adult aromatase-deficient men demonstrated a remarkably low bone mass and unfused epiphyses leading to linear growth into adulthood and above-average body length.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [18]
Once treated with estradiol, epiphyses closed in most aromatase-deficient men.
“Once treated with estradiol, epiphyses closed, BMD increased and disturbances in the lipid profile improved in most of these patients.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [18]
Once treated with estradiol, BMD increased in most aromatase-deficient men.
“Once treated with estradiol, epiphyses closed, BMD increased and disturbances in the lipid profile improved in most of these patients.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [18]
Once treated with estradiol, disturbances in the lipid profile improved in most aromatase-deficient men.
“Once treated with estradiol, epiphyses closed, BMD increased and disturbances in the lipid profile improved in most of these patients.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [18]
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works
Estrogen and the Male Skeleton
Khosla, S., Melton, L. J., & Riggs, B. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8417 · Cited by 308 · see citing works
Estrogen—the Good, the Bad, and the Unexpected
Simpson, E. R., Misso, M., Hewitt, K. N., Hill, R. A., Boon, W. C., Jones, M. E., Kovacic, A., Zhou, J., & Clyne, C. D. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0020 · Cited by 266 · see citing works
Estrogens Are Essential for Male Pubertal Periosteal Bone Expansion
Bouillon, R., Bex, M., Vanderschueren, D., & Boonen, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0602 · Cited by 200 · see citing works
Raven, G., de Jong, F. H., Kaufman, J.-M., & de Ronde, W. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0462 · Cited by 134 · see citing works
Therapeutic uses of aromatase inhibitors in men
de Ronde, W. (2007) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328121aad2 · Cited by 26 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Estrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860 · see citing works
Aromatase inhibitors in men: effects and therapeutic options
de Ronde, W., & de Jong, F. H. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-93 · Cited by 155 · see citing works
- Authors
- Lanfranco, F., Zirilli, L., Baldi, M., Pignatti, E., Corneli, G., Ghigo, E., Aimaretti, G., Carani, C., & Rochira, V.
- Affiliations
- University of Turin (IT)
- University of Modena and Reggio Emilia (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Corresponding author
- Carani, Cesare
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 43
- Issue
- 3
- Pages
- 628-635
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2048362078
- Cited by
- 105
- References
- 6
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 10 · 2019: 4 · 2018: 6 · 2017: 6 · 2016: 5 · 2015: 5 · 2014: 12 · 2013: 2 · 2012: 8
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Bone (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sexual Differentiation and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- aromatase deficiency, CYP19A1, serum estradiol, bone mineral density, skeletal maturation, epiphyseal fusion, eunuchoidism, insulin, asthenozoospermia, cryptorchidism, compound heterozygosity
- MeSH terms
- Adult, Aromatase, Bone and Bones, Bone Diseases, Estradiol, Estrogens, Gigantism, Heterozygote, Humans, Male, Models, Genetic, Mutation, Bone Density, Estrogen Replacement Therapy, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review